<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hamdi, S</style></author><author><style face="normal" font="default" size="100%">Bentahar, I.</style></author><author><style face="normal" font="default" size="100%">Harbadji, H.</style></author><author><style face="normal" font="default" size="100%">Grifi, Fatiha</style></author><author><style face="normal" font="default" size="100%">Bougherira, S.</style></author><author><style face="normal" font="default" size="100%">Filali, T.</style></author><author><style face="normal" font="default" size="100%">Allouda, M.</style></author><author><style face="normal" font="default" size="100%">Mesli, N.</style></author><author><style face="normal" font="default" size="100%">Berber, B.</style></author><author><style face="normal" font="default" size="100%">Bouzid, K.</style></author><author><style face="normal" font="default" size="100%">Sai, R.</style></author><author><style face="normal" font="default" size="100%">Hamladji, RM</style></author><author><style face="normal" font="default" size="100%">Nacer, R. Ahmed</style></author><author><style face="normal" font="default" size="100%">Ait-Ameur, N.</style></author><author><style face="normal" font="default" size="100%">Belhadri, F.</style></author><author><style face="normal" font="default" size="100%">Benakli, Malek</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Epidemiology of Extranodal Diffuse Large B Cell Lymphomas in Algeria: A Study of the Algerian Group of Extranodal Lymphomas (GALEG)</style></title><secondary-title><style face="normal" font="default" size="100%">BloodBlood</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2016</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2016</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">22</style></number><volume><style face="normal" font="default" size="100%">128</style></volume><pages><style face="normal" font="default" size="100%">5403</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Introduction:&amp;nbsp;Primitive extranodal lymphomas are a heterogeneous group of malignant lymphoid hematological developed from the mucosa-associated lymphoid tissue (MATL) or sites that have acquired MALT after repeated stimulation. The particularity of this type of affection reside: the access to diagnosis which is difficult and therapeutic approach which respond to the ATB, antiviral, surgery and RT. They represent 24-48% of lymph node lymphomas and they are increasing. The incidence of lymphoma is growing in the world, it is approximately 16.8 / 105inhabitants. In Algeria in 2012, the incidence of lymph node lymphomas in adults was 2.24 / 100,000. Lymphomas Diffuse large B-cell phenotype (DLBCL) represent 50-60% of lymphomas, it is the most common histological type. Goals of the study: 1-analyze the epidemiological characteristics (gender, age, geographical distribution, annual incidence). 2- Identify anatomical sites. 3- Specify the clinical and prognostic features Patients and methods:&amp;nbsp;It’s is a multicenter, retrospective study over a period between 2010-2014. The study population included all pts over 15 years and having an extranodal DLBCL at 18 hematology centers and 4 cancer centers. Data were collected on data sheets distributed to the various services involved in the study. The diagnosis is made on the histological examination of a biopsy of the affected organ. The clinical, biological and imaging results allowed us to classify and identify prognostic factors for pts. Results:&amp;nbsp;Among 1057 sheets of extranodal lymphomas, the type DLBCL is specified in 562 (53%) cases, distributed in 325 men and 237 women (sex ratio M/F: 1.36). The average age at diagnosis is 51 years (16-88) with a peak in the age group 50-60 years. The overall annual incidence of 0.31/105&amp;nbsp;inhabitants/year and the specific incidence for patients over 15 years is 0.42 / 105inhabitants/year. PS 0-1: 323 / 543pts (60%). Number of pts (pts) by place of care: Annaba 65, Sétif: 60, CAC Constantine: 53, Tizi Ouzou: 49, Blida Cac: 41, CMPC-hematology: 40, Tlemcen: 30, Beni- Méssous- hematology: 29, CAC CPMC: 24, EHUOran: 23, hematology CAC Batna: 22, CHU Oran: 19, HMRUO: 17, Blida-hematology: 16, HCA:16, SBA: 15, CAC Béni-Messous: 14, EPH Mascara: 10, HMRU Oran: 9, Bejaia: 7, hematology CHU Batna: 2, hematology Cne:1. Number of cases according to anatomical localisation: Stomach: 180, Intestine: 31, Colon 12, Tonsils: 70, Cavum: 31, nasal cavities: 11, Bones: 43, mediastinum: 41, SNC: 29, Skin: 25, Rate / MO :15, Thyroid: 12, soft Parties: 10, Breast: 6, lung / pleural: 5, Liver: 5, Others: 36. The clinical symptomatology is very heterogeneous, specifically of the affected organ. Clinical stage is specified in 549 cases, according to Ann Arbor: SCIE: 272 (49%), SCIIE: 149 (27%), SCIIIE: 31 (6%), SCIV: 97 (18%). The International Prognostic Index adjusted for age (IPIaa) include: for pts less than 60 years: Low (F): 70 (23%), lower intermediate (IF): 130 (43%), intermediate high (IE) : 69 (23%), high (H): 32 (11%); for over 60 years Topics: F: 33 (23%), MI: 53 (37%) IE: 41 (28%), E: 17 (12%). Comments:&amp;nbsp;As with other types of lymphoma, there is a male predominance and a peak incidence in the age group 50-60 years. The higher number of pts in the center and east of the country is probably related to a denser population in these regions. The histological type DLBCL at 53% is in agreement whith what it is conventionally reported. The incidence of 0.31/105inhabitants/year extranodal DLBCL is lower than the overall nodal DLBCL, however, the incidence of extranodal NHL is rarely determined. The number of cases of extranodal lymphomas described in this study is certainly below the actual number because this group of disorders is supported by various specialties related to the location of lymphoma. Extranodal lymphomas has a clinical polymorphism, but it is recognized that gastric and tonsillar locations are the most common, the other despite their rarity, require attention from management. This type of lymphoma is characterized by a preponderance of localized stages unlike ganglion lymphomas where the extended stages predominate. Likewise distribution by IPIaa not exceeding one pejorative factor is more common. Conclusion:&amp;nbsp;Extranodal DLBCL are rare, they are characterized by a diversity clinicopathological that challenges us to homogenization of their treatment in multidisciplinary level. Disclosures No relevant conflicts of interest to declare.</style></abstract></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dali, N.</style></author><author><style face="normal" font="default" size="100%">Ait-Ali, H.</style></author><author><style face="normal" font="default" size="100%">Tibiche, A.</style></author><author><style face="normal" font="default" size="100%">Belhadri, F.</style></author><author><style face="normal" font="default" size="100%">Harieche, F</style></author><author><style face="normal" font="default" size="100%">Ahmed-Nacer, R.</style></author><author><style face="normal" font="default" size="100%">Hamladji, RM</style></author><author><style face="normal" font="default" size="100%">Taoussi, S</style></author><author><style face="normal" font="default" size="100%">Oukid, S.</style></author><author><style face="normal" font="default" size="100%">Abad, MT</style></author><author><style face="normal" font="default" size="100%">Boudjerra, N.</style></author><author><style face="normal" font="default" size="100%">Belhani, M.</style></author><author><style face="normal" font="default" size="100%">Bougherira, S.</style></author><author><style face="normal" font="default" size="100%">Grifi, Fatiha</style></author><author><style face="normal" font="default" size="100%">Saidi, D.</style></author><author><style face="normal" font="default" size="100%">Touhami, H.</style></author><author><style face="normal" font="default" size="100%">Mahdad, S.</style></author><author><style face="normal" font="default" size="100%">Bekadja, M. A.</style></author><author><style face="normal" font="default" size="100%">Bouhedda, Z.</style></author><author><style face="normal" font="default" size="100%">Hamdi, S</style></author><author><style face="normal" font="default" size="100%">Kablia, N. Ould</style></author><author><style face="normal" font="default" size="100%">Ardjoun, Fz</style></author><author><style face="normal" font="default" size="100%">Ouaddah, F.</style></author><author><style face="normal" font="default" size="100%">Zouaoui, Z.</style></author><author><style face="normal" font="default" size="100%">Bougofa, S.</style></author><author><style face="normal" font="default" size="100%">Saidi, Mahdia</style></author><author><style face="normal" font="default" size="100%">Benhalilou, M.</style></author><author><style face="normal" font="default" size="100%">Mansour, N. Sidi</style></author><author><style face="normal" font="default" size="100%">Khiat, R.</style></author><author><style face="normal" font="default" size="100%">Mesli, N.</style></author><author><style face="normal" font="default" size="100%">Mehalhal, N.</style></author><author><style face="normal" font="default" size="100%">Brahimi, Z.</style></author><author><style face="normal" font="default" size="100%">Lakhdari, N.</style></author><author><style face="normal" font="default" size="100%">Bendjabellah, B.</style></author><author><style face="normal" font="default" size="100%">Bachiri, A.</style></author><author><style face="normal" font="default" size="100%">Benakli, Malek</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Epidemiology and Clinical Features of Chronic Lymphoid Leukemia. Review of the Algerian Chronic Lymphoid Leukemia Study Group</style></title><secondary-title><style face="normal" font="default" size="100%">BloodBlood</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015</style></date></pub-dates></dates><number><style face="normal" font="default" size="100%">23</style></number><volume><style face="normal" font="default" size="100%">126</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">Introduction:&amp;nbsp;Chronic lymphocytic leukemia (CLL) is the most frequent leukemia of the adult in Europe and North Africa. It is rare on the Asian and African continents. It affects mainly elderly people over 60 years. The main objective is determining the rate of average annual incidence, and secondly establishing the distribution of this complaint according to the different health regions of the country and precise the epidemiological characteristics. Patients and Methods:&amp;nbsp;It is a national, descriptive, retrospective epidemiological study carried out for a period of 05 years : from January 2009 to December 2013. Information collection is done thanks to the setting up of a technical data sheet sent out to the appropriate services. This technical data sheet is about the geographic data of the patient (place of birth, place of residence, place of taking charge of the disease and the date of the diagnosis), anthropologic data (age at the diagnosis, sex), as well as the clinico-biological data. The working of the responses was done on SPSS 19 .0. In our study, the diagnosis is carried before an hyperlymphocytosis &amp;gt; 5000/ mm3, a cytological examination of the blood smear and an immunophenotyping operation by cytometer operation in flow. Results:&amp;nbsp;17 hematology departments have participated in this study with 1210 cases listed, of which 68,1% (824 pts) are men. The average annual recruitment is of 242 cases. The average annual incidence rate, calculated according to the data of the national statistics office is estimated at 0,66 / 100.000 inhabitants.This incidence does not increase over the years and stays relatively stable (2009 = 0,67; 2010 = 0,57; 2011 = 0,63; 2012 = 0,67; 2013 = 0,74/100.000 inhts). The geographic distribution of the pts according to their places of residence, shows that the majority among them are from the north of the country particularly the center (0,80/100.000 inhts). Incidence increases over age, going among men from 0,06 for 100.000 inhts between 30 - 39 years to 11,94 / 100.000 inhts at 80 years and over and among women from 0,04 for 100.000 inhts to 6,08 for 100.000 inhts. The average incidence rate is of 0,85/100.000 inhts among men and of 0,42/100.000 inhts among women. The average age at the diagnosis is of 67,5 years (33 - 98 years). 30,1% (365 pts) incident cases are observed among the patients over 75 years and 14,1% (171 pts) among the patients below the age of 55 years. The profession that is most found is farming 12.2% (78/635 precised). The diagnosis is late in Algeria, the first symptome which brings the patient to consultation is the tumoral syndrome (44% (363 / 825 precised)) in an average diagnosis period of time of 07 months (01 - 96 months). The stage C (classification of Binet) is equally predominant, found in 41,1% (492 / 1172 precised). In terms of biology : the average rate of lymphocytes is of 92500/mm3 (5000-900 000/mm3). The morphological study on blood smear finds 88,2% (1066 / 1208 precised) of typical CLL and 50% of Gambrest cells. The cytometer operation in flow done in 746 cases (61,6%) shows a score of matutes &amp;gt; 4 in 92,3% and in 7,7% is equal to 3. the cytogenetic operation (Caryotype and Fish) done in only one hematology department (CAC of Blida) among 102 patients (8.4%). Comments:&amp;nbsp;The rate of incidence in Algeria is weak compared to that of other countries. The rate of incidence standardized to the world population is of 0,52 cases/100.000 inhts and to the European population is of 0,68 cases p 100.000 inhts. The young age of the population may explain this incidence and that some patients at the stage A are not diagnosed. The CLL affects more frequently men. The average age at the diagnosis is of 67,5 year. However, 30,1% of the incident cases are observed among the patients over 75 years in Algeria versus 45 à 50% of incident cases in Europe and this may be explained by the young age of our population. The CLL are placed 5th among the malignant hemopathies: the rate of incidence for the year 2009 : LNH = 1.96; LH = 1.2; MM = 0.96; AML = 0.85; CLL = 0.67; CML = 0.44; ALL = 0.32. Conclusion:&amp;nbsp;the CLL can be diagnosed and differentiated from the other lymphoproliferative syndromes thanks to the morphological examination of the lymphocytes at the blood smear completed by an immunophenotyping operation of the peripheral blood . This study represents only an epidemiological approach of the CLL in Algeria. The incidence is still weak in our country; it affects as in the other countries the elderly people with a masculin predominance. Disclosures No relevant conflicts of interest to declare.</style></abstract></record></records></xml>